These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 25252913)
1. A recurrent activating PLCG1 mutation in cardiac angiosarcomas increases apoptosis resistance and invasiveness of endothelial cells. Kunze K; Spieker T; Gamerdinger U; Nau K; Berger J; Dreyer T; Sindermann JR; Hoffmeier A; Gattenlöhner S; Bräuninger A Cancer Res; 2014 Nov; 74(21):6173-83. PubMed ID: 25252913 [TBL] [Abstract][Full Text] [Related]
2. Phospholipase C gamma 1 (PLCG1) R707Q mutation is counterselected under targeted therapy in a patient with hepatic angiosarcoma. Prenen H; Smeets D; Mazzone M; Lambrechts D; Sagaert X; Sciot R; Debiec-Rychter M Oncotarget; 2015 Nov; 6(34):36418-25. PubMed ID: 26474454 [TBL] [Abstract][Full Text] [Related]
3. Recurrent CIC Gene Abnormalities in Angiosarcomas: A Molecular Study of 120 Cases With Concurrent Investigation of PLCG1, KDR, MYC, and FLT4 Gene Alterations. Huang SC; Zhang L; Sung YS; Chen CL; Kao YC; Agaram NP; Singer S; Tap WD; D'Angelo S; Antonescu CR Am J Surg Pathol; 2016 May; 40(5):645-55. PubMed ID: 26735859 [TBL] [Abstract][Full Text] [Related]
4. Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway. Murali R; Chandramohan R; Möller I; Scholz SL; Berger M; Huberman K; Viale A; Pirun M; Socci ND; Bouvier N; Bauer S; Artl M; Schilling B; Schimming T; Sucker A; Schwindenhammer B; Grabellus F; Speicher MR; Schaller J; Hillen U; Schadendorf D; Mentzel T; Cheng DT; Wiesner T; Griewank KG Oncotarget; 2015 Nov; 6(34):36041-52. PubMed ID: 26440310 [TBL] [Abstract][Full Text] [Related]
5. Case report: whole exome sequencing of primary cardiac angiosarcoma highlights potential for targeted therapies. Zhrebker L; Cherni I; Gross LM; Hinshelwood MM; Reese M; Aldrich J; Guileyardo JM; Roberts WC; Craig D; Von Hoff DD; Mennel RG; Carpten JD BMC Cancer; 2017 Jan; 17(1):17. PubMed ID: 28056866 [TBL] [Abstract][Full Text] [Related]
6. Frequent and Persistent PLCG1 Mutations in Sézary Cells Directly Enhance PLCγ1 Activity and Stimulate NFκB, AP-1, and NFAT Signaling. Patel VM; Flanagan CE; Martins M; Jones CL; Butler RM; Woollard WJ; Bakr FS; Yoxall A; Begum N; Katan M; Whittaker SJ; Mitchell TJ J Invest Dermatol; 2020 Feb; 140(2):380-389.e4. PubMed ID: 31376383 [TBL] [Abstract][Full Text] [Related]
7. POT1 and Damage Response Malfunction Trigger Acquisition of Somatic Activating Mutations in the VEGF Pathway in Cardiac Angiosarcomas. Calvete O; Garcia-Pavia P; Domínguez F; Mosteiro L; Pérez-Cabornero L; Cantalapiedra D; Zorio E; Ramón Y Cajal T; Crespo-Leiro MG; Teulé Á; Lázaro C; Morente MM; Urioste M; Benitez J J Am Heart Assoc; 2019 Sep; 8(18):e012875. PubMed ID: 31510873 [TBL] [Abstract][Full Text] [Related]
8. Angiogenesis-related gene mutations drive a subset of angiosarcomas. Cancer Discov; 2014 May; 4(5):OF18. PubMed ID: 24795022 [TBL] [Abstract][Full Text] [Related]
9. Recruitment and activation of phospholipase Cgamma1 by vascular endothelial growth factor receptor-2 are required for tubulogenesis and differentiation of endothelial cells. Meyer RD; Latz C; Rahimi N J Biol Chem; 2003 May; 278(18):16347-55. PubMed ID: 12598525 [TBL] [Abstract][Full Text] [Related]
10. Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization. Dougher M; Terman BI Oncogene; 1999 Feb; 18(8):1619-27. PubMed ID: 10102632 [TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor stimulates a novel calcium-signaling pathway in vascular smooth muscle cells. Chandra A; Angle N Surgery; 2005 Oct; 138(4):780-7. PubMed ID: 16269309 [TBL] [Abstract][Full Text] [Related]
12. Competition between SLP76 and LAT for PLCγ1 binding in resting T cells. Jung SH; Jeong JH; Seul HJ; Lee JR Eur J Immunol; 2010 Aug; 40(8):2330-9. PubMed ID: 20544725 [TBL] [Abstract][Full Text] [Related]
13. Phospholipase C-γ1 expression correlated with cancer progression of potentially malignant oral lesions. Ma LW; Zhou ZT; He QB; Jiang WW J Oral Pathol Med; 2013 Jan; 42(1):47-52. PubMed ID: 22671975 [TBL] [Abstract][Full Text] [Related]
14. The mechanism involved in the regulation of phospholipase Cgamma1 activity in cell migration. Piccolo E; Innominato PF; Mariggio MA; Maffucci T; Iacobelli S; Falasca M Oncogene; 2002 Sep; 21(42):6520-9. PubMed ID: 12226755 [TBL] [Abstract][Full Text] [Related]
15. miR-200bc/429 cluster targets PLCgamma1 and differentially regulates proliferation and EGF-driven invasion than miR-200a/141 in breast cancer. Uhlmann S; Zhang JD; Schwäger A; Mannsperger H; Riazalhosseini Y; Burmester S; Ward A; Korf U; Wiemann S; Sahin O Oncogene; 2010 Jul; 29(30):4297-306. PubMed ID: 20514023 [TBL] [Abstract][Full Text] [Related]
16. Protein kinase Cepsilon may act as EGF-inducible scaffold protein for phospholipase Cgamma1. Valkova C; Maerz S; Imhof D; Liebmann C Cell Signal; 2007 Sep; 19(9):1830-43. PubMed ID: 17561374 [TBL] [Abstract][Full Text] [Related]
17. Positive feedback regulation of PLCgamma1/Ca(2+) signaling by PKCtheta in restimulated T cells via a Tec kinase-dependent pathway. Altman A; Kaminski S; Busuttil V; Droin N; Hu J; Tadevosyan Y; Hipskind RA; Villalba M Eur J Immunol; 2004 Jul; 34(7):2001-11. PubMed ID: 15214048 [TBL] [Abstract][Full Text] [Related]
18. Negative regulatory role of overexpression of PLC gamma 1 in the expression of early growth response 1 gene in rat 3Y1 fibroblasts. Shin SY; Ko J; Chang JS; Min DS; Choi C; Bae SS; Kim MJ; Hyun DS; Kim JH; Han MY; Kim YH; Kim YS; Na DS; Suh PG; Lee YH FASEB J; 2002 Oct; 16(12):1504-14. PubMed ID: 12374773 [TBL] [Abstract][Full Text] [Related]